Mojgan Haddad
Overview
Explore the profile of Mojgan Haddad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yardley D, Kaufman P, Huang W, Krekow L, Savin M, Lawler W, et al.
Breast Cancer Res
. 2015 Apr;
17:41.
PMID: 25886996
Introduction: Accurate assessment of HER2 status is critical in determining appropriate therapy for breast cancer patients but the best HER2 testing methodology has yet to be defined. In this study,...
2.
Lathouwers E, Gupta S, Haddad M, Paquet A, De Meyer S, Baugh B
AIDS Res Hum Retroviruses
. 2015 Feb;
31(6):628-35.
PMID: 25684627
HIV-1 samples submitted by clinicians from the United States for routine drug susceptibility testing (PhenoSense GT) were evaluated for genotypic and phenotypic resistance to darunavir and other protease inhibitors (PIs)....
3.
Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler J, Winslow J, et al.
Neuro Oncol
. 2015 Feb;
17(9):1241-9.
PMID: 25681308
Background: Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and significance of expression of...
4.
Goedert J, Swenson L, Napolitano L, Haddad M, Anastos K, Minkoff H, et al.
J Acquir Immune Defic Syndr
. 2014 Oct;
68(1):30-5.
PMID: 25321183
Objective: Evaluate the risk of female breast cancer associated with HIV-CXCR4 (X4) tropism as determined by various genotypic measures. Methods: A breast cancer case-control study, with pairwise comparisons of tropism...
5.
Moradigaravand D, Kouyos R, Hinkley T, Haddad M, Petropoulos C, Engelstadter J, et al.
PLoS Genet
. 2014 Jun;
10(6):e1004439.
PMID: 24967626
Recombination has the potential to facilitate adaptation. In spite of the substantial body of theory on the impact of recombination on the evolutionary dynamics of adapting populations, empirical evidence to...
6.
Picchio G, Rimsky L, Van Eygen V, Haddad M, Napolitano L, Vingerhoets J
Antivir Ther
. 2014 Apr;
19(8):819-23.
PMID: 24704709
Background: The prevalence of rilpivirine resistance-associated mutations (RAMs) in the USA, and their effect on phenotypic susceptibility to rilpivirine and etravirine, was evaluated in clinical samples from HIV-1-infected patients. Methods:...
7.
Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, et al.
Clin Cancer Res
. 2014 Mar;
20(10):2805-13.
PMID: 24668646
Purpose: P95HER2 (p95) is a truncated form of the HER2, which lacks the trastuzumab-binding site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of p95 expression for...
8.
Evans M, Phung P, Paquet A, Parikh A, Petropoulos C, Wrin T, et al.
BMC Bioinformatics
. 2014 Mar;
15:77.
PMID: 24646213
Background: Recent efforts in HIV-1 vaccine design have focused on immunogens that evoke potent neutralizing antibody responses to a broad spectrum of viruses circulating worldwide. However, the development of effective...
9.
Paquet A, Solberg O, Napolitano L, Volpe J, Walworth C, Whitcomb J, et al.
Antivir Ther
. 2014 Feb;
19(4):435-41.
PMID: 24518099
Background: Drug resistance testing and co-receptor tropism determination are key components of the management of antiretroviral therapy for HIV-1-infected individuals. The purpose of this study was to examine trends of...
10.
Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, et al.
Breast Cancer Res Treat
. 2013 Aug;
141(1):43-53.
PMID: 23959396
Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of...